FDA grants fast track status to Artiva's AlloNK for lupus nephritis
The US FDA has granted fast track designation to Artiva Biotherapeutics’ AlloNK plus rituximab or obinutuzumab, for the treatment of lupus nephritis (LN).
Stay updated with breaking news from Fred Aslan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The US FDA has granted fast track designation to Artiva Biotherapeutics’ AlloNK plus rituximab or obinutuzumab, for the treatment of lupus nephritis (LN).
Danish brand OYOY Living Design is continuing its mission to create furniture and objects for the family home with its new Togetherness Award and the winners will be announced at the London Design Fair.
The US Food and Drug Administration (FDA) has granted fast track designation to clinical stage company Artiva Biotherapeutics’s lead programme AB-101.